Taking stock of the drug industry, from the lab to the medicine chestJanuary 30, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Allen G. Breed/AP STAT+ | 'A classic case': A legal expert explains why lawsuits challenging abortion pill restrictions may succeed Carl Tobias, a law professor and former FDA consultant, spoke with STAT about two new lawsuits challenging abortion pill restrictions. By Ed Silverman STAT+ | Pharma wins a key round in a court battle with hospitals over a drug discount program A federal appeals court ruled drug companies have the right to limit discounts to hospitals that participate in the 340B discount program. By Ed Silverman STAT+ | U.K. lawmakers urge Pfizer not to raise the price of its Covid-19 vaccine Several U.K. lawmakers have asked Pfizer not to raise the price of its Covid-19 vaccine, citing concerns such a move could strain the NHS. By Ed Silverman Adobe STAT+ | Medicare Advantage insurers to repay billions under final federal audit rule The Medicare Advantage rule, part of a decade-long feud between insurers and regulators, will likely invite lawsuits from industry groups. By Bob Herman and Tara Bannow STAT+ | FDA names former Oracle executive as new digital health leader The FDA has named Troy Tazbaz, most recently a senior vice president at Oracle, as its new head of digital health. By Lizzy Lawrence More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments